Neuphoria Therapeutics (NEUP) Net Equity Issued and Repurchased (2023 - 2025)
Neuphoria Therapeutics (NEUP) posted quarterly Net Equity Issued and Repurchased of $14.7 million for Q4 2025, up 350.65% quarter-over-quarter from $3.3 million in Q3 2025.
Neuphoria Therapeutics (NEUP) Net Equity Issued and Repurchased (2023 - 2025) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Net Equity Issued and Repurchased for 3 consecutive years, with $14.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $14.7 million; the TTM figure through Mar 2026 stood at $18.6 million (up 531.56% YoY), while the FY2025 annual figure was $1.5 million, down 84.89% from the prior year.
- Net Equity Issued and Repurchased rose to $14.7 million in Q4 2025 per NEUP's latest filing, from $3.3 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $14.7 million in Q4 2025 and bottomed at $288782.0 in Q4 2023.
- Historically, Net Equity Issued and Repurchased has averaged $3.7 million across 3 years, with a median of $1.8 million in 2024.
- On a YoY basis, Net Equity Issued and Repurchased climbed as much as 42.68% in 2025 and fell as far as 66.83% in 2025.
- Neuphoria Therapeutics' Net Equity Issued and Repurchased stood at $288782.0 in 2023, then jumped by 635.76% to $2.1 million in 2024, then surged by 590.07% to $14.7 million in 2025.
- Business Quant data shows NEUP's Net Equity Issued and Repurchased at $14.7 million in Q4 2025, $3.3 million in Q3 2025, and $704675.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Neuphoria Therapeutics | 21.28 Mn | 1.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14.66 Mn |
| Dec 31, 2025 | 14.66 Mn |
| Sep 30, 2025 | 3.25 Mn |
| Sep 30, 2025 | 3.25 Mn |
| Jun 30, 2025 | 704,675.00 |
| Jun 30, 2025 | 704,675.00 |
| Mar 31, 2025 | 823,601.00 |
| Mar 31, 2025 | 823,601.00 |
| Jun 30, 2024 | 2.12 Mn |
| Jun 30, 2024 | 2.12 Mn |
| Mar 31, 2024 | 1.44 Mn |
| Mar 31, 2024 | 1.44 Mn |
| Dec 31, 2023 | 288,782.00 |
| Dec 31, 2023 | 288,782.00 |
| Sep 30, 2023 | 6.26 Mn |
| Sep 30, 2023 | 6.26 Mn |